Please login to the form below
Belviq
This page shows the latest Belviq news and features for those working in and with pharma, biotech and healthcare.
Eisai agrees to pull obesity drug Belviq after safety alert
Weight-loss drug linked to increased risk of cancer. Eisai has moved swiftly to comply with an FDA request to pull its obesity drug Belviq off the market after it was ... The decision to withdraw Belviq (lorcaserin) and once-daily line extension Belviq
Latest news
-
Novo Nordisk taps Noom for digital help with its push into obesity
developers. There is a handful of approved drug therapies – including GlaxoSmithKline’s/Roche’s lipase inhibitor, Xenical (orlistat), Eisai’s Belviq (lorcaserin) and Vivus Qsymia (phentermine/topiramate) – but none have been
-
Eisai takes control of weight loss drug Belviq from Arena
Frustrated with lacklustre sales growth, Eisai has bought global rights to weight-loss drug Belviq from its originator Arena Pharmaceuticals. ... The move comes after the launch of a new once-daily formulation of lorcaserin called Belviq XR in the US,
-
Eisai launches thyroid cancer therapy Lenvima in UK
Belviq (lorcaserin).
-
Takeda files block on generic diet pill launch
But despite being third to market among the new generation of obesity therapies after Eisai and Arena's Belviq (lorcaserin) and Vivus' Qsymia (phentermine/topiramate), both approved 18 months ago, Orexigen
-
Eisai to share clinical trial data via external website
Eisai is forthcoming in its approach to digital outreach, this year setting up an online community of personal weight loss stories as part of its marketing efforts for obesity brand Belviq.
More from news
Approximately 7 fully matching, plus 25 partially matching documents found.
Latest Intelligence
-
Is obesity really a problem in Brazil?
Shaloo is manager, health outcomes research at Kantar Health, and Lance is director, global value and access strategy neurology, global market access lead: Belviq, ABBA, HAND and AVA, market access lead
-
Pharma deals during November 2012
15. Arena / Ildong Pharma. Marketing and supply agreement. BELVIQ for weight loss.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Anthony Zook resigns as Vivus CEO
This coup was led by investment group First Manhattan Co, which had attempted to replace the entire board of Vivus after Qsymia fell behind rival obesity drug Belviq (lorcaserin) from Arena
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
Evoke Mind+Matter
We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
